DocMorris Toekomstige groei

Future criteriumcontroles 1/6

DocMorris zal naar verwachting groeien in winst en omzet met respectievelijk 57.3% en 16.3% per jaar. De winst per aandeel zal naar verwachting groeien met 55.8% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting -6.8% zijn.

Belangrijke informatie

57.3%

Groei van de winst

55.8%

Groei van de winst per aandeel

Consumer Retailing winstgroei	11.3%
Inkomstengroei	16.3%
Toekomstig rendement op eigen vermogen	-6.8%
Dekking van analisten	Good
Laatst bijgewerkt	21 Nov 2024

Recente toekomstige groei-updates

Recent updates

Earnings Update: Zur Rose Group AG (VTX:ROSE) Just Reported And Analysts Are Trimming Their Forecasts

Mar 22

Some Zur Rose Group AG (VTX:ROSE) Analysts Just Made A Major Cut To Next Year's Estimates

Mar 20

What Kind Of Investors Own Most Of Zur Rose Group AG (VTX:ROSE)?

Feb 23

Is Zur Rose Group's (VTX:ROSE) Share Price Gain Of 210% Well Earned?

Jan 19

Zur Rose Group AG (VTX:ROSE) Is Expected To Breakeven In The Near Future

Dec 15

Winst- en omzetgroeiprognoses

SWX:DOCM - Toekomstschattingen van analisten en financiële gegevens uit het verleden (CHF Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	1,556	-15	-25	35	10
12/31/2025	1,259	-70	-68	-36	11
12/31/2024	1,038	-92	-77	-44	12
6/30/2024	1,003	-97	-92	-63	N/A
3/31/2024	986	-107	-103	-75	N/A
12/31/2023	969	-118	-115	-87	N/A
9/30/2023	934	-132	-124	-90	N/A
6/30/2023	899	-146	-129	-93	N/A
3/31/2023	915	-158	-136	-95	N/A
12/31/2022	931	-171	-144	-97	N/A
9/30/2022	1,156	-202	-178	-126	N/A
6/30/2022	1,381	-232	-212	-155	N/A
3/31/2022	1,554	-229	-203	-143	N/A
12/31/2021	1,727	-226	-194	-131	N/A
9/30/2021	1,673	-193	-155	-87	N/A
6/30/2021	1,619	-160	-116	-43	N/A
3/31/2021	1,548	-148	-122	-55	N/A
12/31/2020	1,477	-136	-127	-68	N/A
9/30/2020	1,431	-112	-138	-88	N/A
6/30/2020	1,385	-88	-149	-108	N/A
3/31/2020	1,370	-70	-137	-95	N/A
12/31/2019	1,356	-52	-124	-83	N/A
9/30/2019	1,314	-45	N/A	N/A	N/A
6/30/2019	1,272	-39	-67	-35	N/A
3/31/2019	1,240	-39	-66	-34	N/A
12/31/2018	1,207	-39	-65	-33	N/A
9/30/2018	1,166	-37	N/A	N/A	N/A
6/30/2018	1,125	-36	-59	-30	N/A
3/31/2018	1,061	-36	N/A	N/A	N/A
12/31/2017	990	-36	N/A	-22	N/A
9/30/2017	953	-34	N/A	-21	N/A
6/30/2017	915	-31	N/A	-21	N/A
3/31/2017	900	-21	N/A	N/A	N/A
12/31/2016	884	-13	N/A	-14	N/A
9/30/2016	873	-4	N/A	N/A	N/A
6/30/2016	861	6	N/A	N/A	N/A
3/31/2016	847	4	N/A	N/A	N/A
12/31/2015	838	3	N/A	19	N/A
9/30/2015	857	4	N/A	N/A	N/A
6/30/2015	875	5	N/A	N/A	N/A
3/31/2015	898	6	N/A	N/A	N/A
12/31/2014	920	7	N/A	7	N/A
9/30/2014	919	-3	N/A	N/A	N/A
6/30/2014	919	-13	N/A	N/A	N/A
3/31/2014	917	-14	N/A	N/A	N/A
12/31/2013	916	-15	N/A	2	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat DOCM de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat DOCM de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat DOCM de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: De omzet van DOCM ( 16.3% per jaar) zal naar verwachting sneller groeien dan de markt Swiss ( 4.2% per jaar).

Hoge groei-inkomsten: De omzet van DOCM ( 16.3% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Er wordt voorspeld dat DOCM binnen 3 jaar verliesgevend zal zijn.

DocMorris Toekomstige groei

Future criteriumcontroles 1/6

Belangrijke informatie

Recente toekomstige groei-updates

Price target decreased by 9.9% to CHF60.50

Price target decreased by 9.1% to CHF70.92

No longer forecast to breakeven

Price target decreased by 10% to CHF88.50

Price target increased by 7.5% to CHF99.24

Recent updates

DocMorris AG's (VTX:DOCM) Subdued P/S Might Signal An Opportunity

Price target decreased by 9.9% to CHF60.50

Does DocMorris (VTX:DOCM) Have A Healthy Balance Sheet?

Price target decreased by 9.1% to CHF70.92

No longer forecast to breakeven

First half 2024 earnings released: CHF3.22 loss per share (vs CHF4.99 loss in 1H 2023)

New minor risk - Profitability

Price target decreased by 10% to CHF88.50

DocMorris AG to Report First Half, 2025 Results on Aug 19, 2025

DocMorris AG to Report Q3, 2025 Results on Oct 16, 2025

New minor risk - Shareholder dilution

Price target increased by 7.5% to CHF99.24

Price target increased by 7.4% to CHF95.49

Full year 2023 earnings released: CHF10.07 loss per share (vs CHF15.88 loss in FY 2022)

Price target increased by 7.2% to CHF85.27

Price target increased by 7.9% to CHF84.09

Consensus EPS estimates fall by 27%

Consensus EPS estimates upgraded to CHF4.58 loss

Price target increased by 8.7% to CHF75.00

Price target increased by 12% to CHF72.33

Price target increased by 9.1% to CHF69.00

Consensus EPS estimates fall by 11%

Consensus EPS estimates upgraded to CHF3.46 loss

New minor risk - Profitability

DocMorris AG to Report Fiscal Year 2023 Results on Mar 21, 2024

Price target increased by 10% to CHF64.86

Consensus EPS estimates upgraded to CHF3.21 loss, revenue downgraded

Price target increased by 10% to CHF57.33

First half 2023 earnings released: CHF4.99 loss per share (vs CHF8.05 loss in 1H 2022)

Medbase AG acquired Swiss business of Zur Rose from Zur Rose Group AG (SWX:ROSE).

Medbase AG acquired Swiss business of Zur Rose from Zur Rose Group AG (SWX:ROSE).

Price target decreased by 30% to CHF37.96

Price target decreased to CHF73.14

Price target decreased to CHF78.73

Reade Griffith acquired an unknown minority stake in Zur Rose Group AG (SWX:ROSE).

Would Zur Rose Group (VTX:ROSE) Be Better Off With Less Debt?

Price target decreased to CHF107

First half 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased to CHF134

Zur Rose Group AG, Annual General Meeting, May 04, 2023

Price target decreased to CHF154

Zur Rose Group AG Announces Resignation of Betül Susamis Unaran, Chief Strategy and Digital Officer and as Member of the Executive Board

Price target decreased to CHF197

Zur Rose Group AG to Report First Half, 2022 Results on Aug 18, 2022

Price target decreased to CHF281

Price target decreased to CHF303

Consensus forecasts updated

Price target decreased to CHF387

Price target decreased to CHF404

No longer forecast to breakeven

We Think Zur Rose Group (VTX:ROSE) Has A Fair Chunk Of Debt

We Think Zur Rose Group (VTX:ROSE) Has A Fair Chunk Of Debt

First half 2021 earnings released: CHF8.03 loss per share (vs CHF6.03 loss in 1H 2020)

Consensus forecasts updated

No longer forecast to breakeven

No longer forecast to breakeven

Non-Executive Director has left the company

Is Zur Rose Group (VTX:ROSE) Using Too Much Debt?

Full year 2020 earnings released: CHF14.95 loss per share (vs CHF6.04 loss in FY 2019)

Earnings Update: Zur Rose Group AG (VTX:ROSE) Just Reported And Analysts Are Trimming Their Forecasts

Full year 2020 earnings released

Some Zur Rose Group AG (VTX:ROSE) Analysts Just Made A Major Cut To Next Year's Estimates

Zur Rose Group AG Provides Earnings Guidance for the Year 2021

What Kind Of Investors Own Most Of Zur Rose Group AG (VTX:ROSE)?

Price target raised to CHF453

New 90-day high: CHF476

Price target raised to CHF400

Zur Rose Group AG to Report First Half, 2021 Results on Aug 19, 2021

Is Zur Rose Group's (VTX:ROSE) Share Price Gain Of 210% Well Earned?

New 90-day high: CHF380